Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2014, 39(9): 607
ISSN 0377-8282
Copyright 2014 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2014.039.09.2182240
 
 
AN-2728: Phosphodiesterase PDE4 inhibitor, treatment of atopic dermatitis, treatment of psoriasis
Reviriego, C.
 
 
Psoriasis and atopic dermatitis are non-contagious inflammatory skin diseases with a chronic and relapsing course. Currently, although several treatments are available to control these disorders, other therapies are under investigation. The available therapies help relieve the symptoms and increase the time between flare-ups. However, due to the chronic course of these diseases, becoming refractory to long-term treatment is often a possibility. AN-2728 is an investigational drug targeting the inflammatory pathway. It is a novel boron-containing molecule that inhibits the release of proinflammatory cytokines by binding to the active water in the bimetal center of the active site of the phosphodiesterase PDE4 enzyme. AN-2728 has shown a promising safety profile and is generally well tolerated following topical application in patients with mild to moderate psoriasis and atopic dermatitis. In several phase II studies, the primary endpoint has been successfully achieved.


Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy